Skip to Content

Ixempra Approval History

FDA Approved: Yes (First approved October 16, 2007)
Brand name: Ixempra
Generic name: ixabepilone
Dosage form: Injection
Company: R-Pharm US
Treatment for: Breast Cancer

Ixempra (ixabepilone) is a semisynthetic analog of epothilone B indicated for the treatment of patients with metastatic or locally advanced breast cancer.

Development History and FDA Approval Process for Ixempra

DateArticle
Oct 17, 2007Approval FDA Approves Ixempra (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Jun 19, 2007FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide